Abstract 6002
Background
Although cancer patients are known to be at higher risk of infection and its subsequent complications, the magnitude of infection-related mortality in cancer patients remains unknown. In this study, data from Surveillance, Epidemiology, and End Results Program (SEER) were explored in order to identify how far infection was identified as the cause of death in cancer patients in the United States between 2010 and 2016.
Methods
Data were obtained using SEER*Stat version 8.3.5 where (SEER 18 Regs Nov 2018 Submission) was used as the data source. Only cases with malignant behavior, known age, and those in research database were included. Analysis was made for patients who were diagnosed between 2010 and 2016 whose vital status was reported as "dead" at the time of study cut-off. Data about cause of death were exported using case-listing session in SEER*Stat and were analyzed using SPSS version 25.
Results
1,012,769 cases were included in the final data analysis. Infection was identified as the cause of death in 1.89% of cases (n = 19,155). Infection-related mortality was much higher in patients diagnosed with hematological malignancies (3.6%, n = 3,472) compared with non-hematological malignant diseases (1.7%, n = 15683). Deaths related to infection were also higher in males (2.2%, n = 11,827) compared with females (1.6%, n = 7,328).
Conclusions
Although infection is perceived as a major cause of morbidity and mortality in cancer patients, its current magnitude may be lower than expectations. Infection-related mortality showed higher prevelance in males and in patients with hematological malignancies.
Clinical trial identification
N/A
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract